Three European biotech companies have received loans totalling €100 million from the European Investment Bank (EIB) enabling them to advance imaging and cell and gene therapy technologies, as well as individualised medicines for cancer. The EIB is the long-term lending institution of the European Union and owned by the EU member states. The three biotech companies are France-based Median Technologies SA, Italy-based MolMed SpA and Germany-based BioNTech SE.
